The way you think, the way you behave, the way you eat, can influence your life by 30 to 50 years.

-Deepak Chopra

 

PNA Spotlight: Dr. Manish Aghi

This month the PNA Spotlight focuses on Dr. Manish K. Aghi.Dr. Manish Aghi is a neurosurgeon specializing in brain tumors at UCSF Medical Center. He cares for adult patients with a wide range of conditions, including astrocytomas and anaplastic astrocytomas, oligodendrogliomas, glioblastomas, meningiomas and pituitary adenomas. As principal investigator at the UCSF Brain Tumor Research Center, his interests include glioblastoma angiogenesis, mechanisms of glioblastoma resistance to anti-angiogenic therapy and experimental glioblastoma therapies such as cancer-killing viruses.
Professor Aghi earned his medical degree and a doctoral degree in neurosciences from Harvard Medical School. He completed a residency in neurosurgery at Massachusetts General Hospital. He is a member of the Society for Neuro-Oncology, American Association of Neurological Surgeons, Congress of Neurological Surgeons and Pituitary Network Association. Among his honors are the Preuss and Mahaley awards from the American Association of Neurological Surgeons, and the Ronald L. Bittner Award, Synthes Skull Base Award and Integra Foundation Award from the Congress of Neurological Surgeons.
His answers follow.

Read more

PNA Medical Corner: Pituitary Centers of Excellence

This month the PNA Medical Corner focuses on an article co-authored by several members and colleagues of the PNA: Drs. Chanson, Kaiser, Laws, van der Lely, and Melmed. It addresses a topic that PNA has sought to promote for decades: the designation of Pituitary Centers of Excellence, where patients can get highly specialized care

Link: https://pubmed.ncbi.nlm.nih.gov/37640885/

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

Read More

Featured News and Updates

The FDA has approved NGENLA (somatrogon-ghla)

The FDA has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.

See the Press Release here>

News Articles April 2026

Pituitary story: 10-year-old pituitary patient honored for bravery

 A ten-year-old Scottish girl has been honored for her bravery as she underwent surgery for a pituitary tumor. Read more:  https://www.northern-times.co.uk/news/she-s-an-absolute-star-inverness-pupil-honoured-for-brave-431104/

Teen overcomes Cushing’s Disease

 

A 17-year-old girl in North Carolina is doing well after surgery to remove a pituitary tumor caused by Cushing’s Disease. She is an avid runner who suffered headaches and fatigue before her diagnosis.  Read more: https://www.wect.com/2026/04/01/believe-them-teen-runner-diagnosed-with-rare-cushings-disease-after-years-symptoms/

 

Pituitary story: Cushing’s at age 27

A 27-year-old woman experienced a lack of menses and unexplained weight gain before being diagnosed with Cushing’s disease. She had surgery at Cleveland Clinic in Florida and has returned to a normal life. Read more: https://my.clevelandclinic.org/patient-stories/960-in-her-twenties-yoselin-needed-pituitary-tumor-surgery

 

 

Mobile MRI during pituitary surgery

An article on MSN.com looks at the use of mobile brain scanners during pituitary surgery in Canada.  Read more: https://www.msn.com/en-ca/health/other/mobile-brain-scans-sound-like-science-fiction-but-they-re-now-helping-more-canadian-patients/ar-AA1YlZWc

Research Articles

Research Articles April 2026

Pituitary Tumors

Astragaloside IV targets TUBB4B to inhibit proliferation and promote apoptosis of pituitary tumor cells via the STMN1/ERK pathway.

Li J, Qu Y, Zhang W, Yang Z, Zeng Y, Xu J, Xie K, Liu Q.Int J Mol Med. 2026 Jun;57(6):151. doi: 10.3892/ijmm.2026.5822. Epub 2026 Apr 3.

 

[Endocrine inactive pituitary microadenomas: current data on natural history and follow-up approaches].

Dzhatieva DN, Pigarova EA, Dzeranova LK.Zh Vopr Neirokhir Im N N Burdenko. 2026;90(2):98-102. doi: 10.17116/neiro20269002198.


[Impact of cabergoline on fibrosis in prolactinoma].

Matsueva IA, Paltsev AA, Guseva KA, Tsoy UA, Grineva EN.Zh Vopr Neirokhir Im N N Burdenko. 2026;90(2):85-91. doi: 10.17116/neiro20269002185.


[Hypothalamic obesity in adults with craniopharyngiomas: prevalence and risk factors before and after neurosurgical treatment].

Klochkova IS, Astafyeva LI, Kutin MA, Konovalov AN, Sidneva YG, Shkarubo AN, Kalinin PL.Zh Vopr Neirokhir Im N N Burdenko. 2026;90(2):77-84. doi: 10.17116/neiro20269002177.

 

Gonadal recovery in men with prolactinomas on cabergoline: 6-month testosterone levels as a predictor of testosterone replacement timing.

Fedai NK, Uzun N, Bostan H, Kizilgul M, Demirci T, Cakal E, Ucan B.Hormones (Athens). 2026 Apr 2. doi: 10.1007/s42000-026-00766-3. Online ahead of print.


Visual outcomes after pituitary adenoma surgery: Associated factors and longitudinal progression in a prospective single-centre study.

Lozouet M, Saadoun A, Ménard A, Aldea S, Jaoude SA, Heran F, Yavchitz A, Philibert M, Chauvet D.Clin Neurol Neurosurg. 2026 Mar 28;267:109409. doi: 10.1016/j.clineuro.2026.109409. Online ahead of print.

 

Machine Learning-Based models in prediction of Ki-67 in pituitary adenoma: A systematic review and Meta-Analysis.

Hajikarimloo B, Mohammadzadeh I, Tos SM, Bahri A, Sabaghian A, Habibi MA.Endocrine. 2026 Apr 1;91(1):118. doi: 10.1007/s12020-026-04590-y.

 

Pituitary disorders

Recurrent pituitary apoplexy: experience from a national registry and review of the literature.

Biagetti B, Cordero Asanza E, Iglesias P, Camara R, Asla Q, Vicente A, Martinez-Saez E, Sarria-Estrada S, Puig-Domingo M, Araujo-Castro M.Ther Adv Endocrinol Metab. 2026 Mar 28;17:20420188261434641. doi: 10.1177/20420188261434641. eCollection 2026.


Post-Traumatic Pituitary Stalk Transection Syndrome.

Albusaidi R, AlHatmi A, Al Shidhani A, Al-Ajmi E.Sultan Qaboos Univ Med J. 2026 Mar 7;26(1):230-232. doi: 10.18295/2075-0528.2977. eCollection 2026.


The impact of a non-functioning pituitary adenoma on life – A qualitative study of patients’ experiences.

Al-Shamkhi N, Edén Engström B, Rask E, Anderzén-Carlsson A.PLoS One. 2026 Mar 31;21(3):e0345909. doi: 10.1371/journal.pone.0345909. eCollection 2026.

 

Combined surgery and proton radiotherapy in the management of craniopharyngiomas: an update with paradigmatic and challenging case scenarios.

Valeri F, Zoli M, Lillo S, Tengattini F, Colombo F, Pasquini E, Salierno G, Carretta A, D’Ambrosio L, Babaei D, Agosti E, Mattogno PP, Fontanella MM, Lauretti L, Mazzatenta D, Doglietto F, Iannalfi A.Neurosurg Rev. 2026 Mar 31;49(1):331. doi: 10.1007/s10143-026-04258-1.

 

Cushing’s

Traditional Chinese Medicine in Cushing’s Syndrome: A Narrative Review of Pathophysiology and Potential Therapeutic Effects.

Chen B, He C, Han L, Wang H, Ma Y, Wang R, Cai X.Onco Targets Ther. 2026 Feb 6;19:571776. doi: 10.2147/OTT.S571776. eCollection 2026.

 

Symptom management with osilodrostat in multiple endocrine neoplasia type 1 with a Cushing syndrome presentation.

Jamal HF.JCEM Case Rep. 2026 Mar 31;4(4):luag039. doi: 10.1210/jcemcr/luag039. eCollection 2026 Apr.


Persistent remission after steroidogenesis inhibitor discontinuation in Cushing disease: a case series.

Mangone A, Sala E, Carosi G, Sindaco GD, Mungari R, Cremaschi A, Petria I, Noschese G, Lotito V, Mantovani G, Ferrante E.Pituitary. 2026 Apr 1;29(2):68. doi: 10.1007/s11102-026-01668-8.

 

Clinical characteristics, diagnosis, and treatment of Cushing’s syndrome: analysis of a multicenter registry in Antioquia, Colombia.

Rivera-Martínez WA, Ramírez Castaño MJ, Cruz Calderón S, Díaz Posada NA, Gutiérrez Restrepo J, Román-González A, Aristizábal Henao N, Castaño Ceballos PA, Tobón Ospina CI, Donado Gómez JH, López Pompey N, Builes-Montaño CE.Ther Adv Endocrinol Metab. 2026 Mar 28;17:20420188261434078. doi: 10.1177/20420188261434078. eCollection 2026.


Prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease in Craniopharyngioma Patients Using Non-Invasive Investigations.

Nitya AAV, Ghosh J, Taneja S, Singla V, Kalra N, Dutta P.Indian J Endocrinol Metab. 2026 Jan-Feb;30(1):79-84. doi: 10.4103/ijem.ijem_821_25. Epub 2026 Feb 27.


A proposed classification and scoring system predicting gross total resection of recurrent and residual pituitary adenoma: a retrospective study.

Quan W, Zhao DW, Li L, Chen HR, Wang L, Hu SL, Hu R.World Neurosurg. 2026 Mar 28:124958. doi: 10.1016/j.wneu.2026.124958. Online ahead of print.PMID: 41912140

 

 

Acromegaly

Meningoencephalitis and secondary pituitary abscess in a 16-year-old patient with gigantism.

Wissa M, Strenger V, Weinhandl G, Braun H, Wolfsberger S, Micko A.JCEM Case Rep. 2026 Apr 1;4(4):luag032. doi: 10.1210/jcemcr/luag032. eCollection 2026 Apr.

 

The silent surden: Alexithymia and quality of life in acromegaly patients.

Soltanova L, Aygun AB, Kocaman BB, Muradov I, Taze SS, Turan S, Kadioglu P, Durcan E.Endocrine. 2026 Apr 2;91(1):135. doi: 10.1007/s12020-026-04606-7.

 

To test or not to test: what we have learnt from 50 years of dynamic testing in acromegaly.

De Marinis L, Chiloiro S, Mancini A, Giambò P, Giampietro A, Bianchi A, Pontecorvi A, Giustina A.Pituitary. 2026 Mar 31;29(2):67. doi: 10.1007/s11102-026-01649-x.


Acromegaly is Associated with an Increased Incidence of Primary Malignant Tumors: Data from a National Study in Sweden.

Tsatsaris E, Robèrt J, Burman P, Berinder K, Bonelli L, Dahlqvist P, Höybye C, Ragnarsson O, Vouzouneraki K, Åkerman AK, Ekman B, Engström BE.J Clin Endocrinol Metab. 2026 Mar 30:dgag137. doi: 10.1210/clinem/dgag137. Online ahead of print.PMID: 41913644

 

Acromegaly-Physiopathology and etiology.

Castinetti F.Vitam Horm. 2026;131:83-102. doi: 10.1016/bs.vh.2026.01.001. Epub 2026 Jan 28.PMID: 41912301 Review.

 

Co-secreting pituitary adenomas in acromegaly: Classification, diagnosis, and treatment strategies.

Biagetti B, Araujo-Castro M.Vitam Horm. 2026;131:41-57. doi: 10.1016/bs.vh.2025.06.002. Epub 2025 Dec 3.


Acromegaly and histopathology.

Caballero GA, Ribalta T, Aldecoa I.Vitam Horm. 2026;131:293-334. doi: 10.1016/bs.vh.2025.10.007. Epub 2025 Nov 13.PMID: 41912298 Review.


New molecular markers of response to medical therapy in acromegaly.

Raventós A, Gil J, Marques-Pamies M, de Pedro-Campos P, Puente de la Vega C, Picó A, Lamas C, Delgado E, Menéndez E, Serra G, Bernabéu I, Villar R, Ferri J, Mariaca K, Martínez R, Marazuela M, Araujo-Castro M, Biagetti B, Jordà M, Valassi E, Puig-Domingo M; ACROMICS investigators.Vitam Horm. 2026;131:265-292. doi: 10.1016/bs.vh.2025.10.006. Epub 2025 Nov 12.

 

Acromegaly and genetics.

de Lapiscina IM, Baquero C, Castaño L.Vitam Horm. 2026;131:235-263. doi: 10.1016/bs.vh.2025.10.008. Epub 2025 Dec 16.PMID: 41912295 Review.

 

Gigantism.

Donato S, Regala C, Marques P.Vitam Horm. 2026;131:195-234. doi: 10.1016/bs.vh.2025.10.005. Epub 2026 Feb 16.PMID: 41912294 Review.

 

Hormonal Health

Male testosterone synthesis disorders: oxidative stress pathways, regulatory mechanisms, potential of antioxidant therapy, and botanical medicine prospects.

Wu H, Jian MT, Ning G, Li BN, Peng AJ, Wang HY, Tang X, Zhou X.Asian J Androl. 2026 Apr 3. doi: 10.4103/aja2025105. Online ahead of print.

 

From the perspective of prolactin: a view on obesity.

Wang Y, Luo D, Fang G, Ge M, Huang Y, Deng H.Front Endocrinol (Lausanne). 2026 Mar 16;17:1762596. doi: 10.3389/fendo.2026.1762596. eCollection 2026.

 

Gonadotropins Across the Lifespan: Their role in the Neurodevelopment-Neurodegeneration Continuum.

Galbraith JA, Elhassan MZ, Rocha JF, Al Mozani TA, Fredericks CA.Yale J Biol Med. 2026 Mar 31;99(1):199-215. doi: 10.59249/EVST3084. eCollection 2026 Mar.

 

Neonatal Hypopituitarism.

Dayno AN, Crowley J, Bamba V, Bhoj EJK, Shekdar K, McCormack SE.Neoreviews. 2026 Apr 1;27(4):e211-e221. doi: 10.1542/neo.27-4-002.

 

Unconventional Uses of Human Growth Hormone.

Lisbona-Buzali M, Edid-Jaris G, Alegre-Lifshitz A, Mercado-Medrez S, Taniguchi-Ponciano K, Marrero-Rodriguez D, Mercado M.Arch Med Res. 2026 Mar 30;57(5):103412. doi: 10.1016/j.arcmed.2026.103412. Online ahead of print.PMID: 41915988 Review.

 

Comment on: Oxytocin: a neglected hormone in pituitary disease – From function to the diagnosis of a deficiency, resulting clinical relevance, and potential treatment options in endocrinology.

Elia A.Arch Endocrinol Metab. 2026 Jun 1;70(3):e260025. doi: 10.20945/2359-4292-2026-0025.

 

TRH can stimulate the release of two POMC-derived pituitary hormones, ACTH and MSH, in medaka.

Yamakawa M, Gajbhiye DS, Golan M, Kanda S.Endocrinology. 2026 Mar 30:bqag037. doi: 10.1210/endocr/bqag037. Online ahead of print.

 

 

 

 

Copyright © 2024 Pituitary Network Association All rights reserved.

Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.

Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]

You are receiving this Newsletter because you have shown interest in receiving information about our activities.

If you do not want to receive any more emails from PNA, Unsubscribe.